Gelteq Ltd
NASDAQ:GELS
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| AU |
G
|
Gelteq Ltd
NASDAQ:GELS
|
8.5m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
932.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
271B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
236.5B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
287.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153.8B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121B USD |
Loading...
|
Market Distribution
| Min | -6 907 100% |
| 30th Percentile | 21.6% |
| Median | 38.3% |
| 70th Percentile | 58.2% |
| Max | 2 095.9% |
Other Profitability Ratios
Gelteq Ltd
Glance View
Gelteq Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2024-10-29. Gelteq Limited is an Australia-based clinical and science-based company. The firm is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The firm offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The firm also offers a highly versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Gelteq Ltd is 30.4%, which is below its 3-year median of 35.9%.
Over the last 2 years, Gelteq Ltd’s Gross Margin has decreased from 38.7% to 30.4%. During this period, it reached a low of 30.4% on Jun 30, 2025 and a high of 38.7% on Jun 30, 2023.
